Program
Content
7th Annual Wall Street Unplugged
Management’s Guide to Wall Street & Capital Markets
July 28, 2011 – New York, NY
‘
Sponsored by
Agenda
8:30‐9:30 9:30‐10:00 10:00‐10:15 10:15‐11:00 11:00‐11:30 11:30‐12:00 12:00‐1:00 1:00‐1:45 1:45‐2:30 2:30‐3:00 3:00‐3:15 3:15‐3:45 3:45 ‐4:15 4:15‐5:00 5:00‐5:15 6:00‐8:00 Registration and Breakfast Implications of Healthcare Reform on FDA Processes Angeliki Kotsianti, MD, PhD – Director, Global R&D, Pfizer Carlos Cordon‐Cardo, MD, PhD – Chair of the Dept. of Pathology, Mount Sinai Medical Center Rhonda Greenapple, MSPH – President and Founder, Reimbursement Intelligence Moderator: Rosemary Mazanet, MD, PhD – Senior Advisor, The Trout Group Social Media: New Trends in Online Marketing Justin Schreiber– President & CEO, Executive Video Exploring Innovative Financing Danielle Peters – Fabiani & Company, Consultant Gary L. Disbrow, PhD – Biomedical Advanced Research and Development Authority John Partigan, J.D. – Partner, Securities Practice Group Leader, Nixon Peabody Karin Hehenberger – SVP, Strategic Alliances, Juvenile Diabetes Foundation Michael Herman – SVP, Research & Investments, Royalty Pharma Moderator: Christopher D. Earl, PhD Investor Communication: Presentation Content & Style Presenter: Jan Schultink – CEO, Idea Transplant Minimizing Dilution in Capital Raising Dennis Turpin, CA – CFO, AEterna Zentaris, Inc. Frederick W. Driscoll – CFO, Novavax, Inc. Richard D. Katz, MD – CFO, Icagen, Inc. Shalini Sharp – CFO, Agenus, Inc. Moderator: Dean Colucci – President and General Counsel, McNicoll, Lewis & Vlak Networking Lunch Buy‐Side Perspectives: Communication, Targeting & Analysis Christiana Bardon, MD – Chief Investment Officer, Burrage Capital David Sable, MD – Portfolio Manager, Special Situations Fund Fara Berkowitz, Pharm D – Managing Director, Meadowvale Partners, LLC. Tom Brakel, MD – Senior Portfolio Manager, Federated Investors, Inc. Moderator: Thomas Fechtner – Vice President, The Trout Group Sell‐Side Perspectives: Analyzing Opportunities in a Dynamic Sector & Marketplace Jason Butler, PhD – Research Analyst, JMP Securities Josh Schimmer, MD – Research Analyst, Leerink Swann Sapna Srivastava, PhD – Research Analyst, Goldman Sachs Moderator: Franklin Berger, CFA – Managing Director, FMB Research Funding Innovation: Accessing Risk Capital Gur Roshwalb, MD – Vice President, Venrock Jay Cecil – Managing Director, Caxton Advantage Moderator: Mike Nowak – Managing Director, Yorkville Advisors Coffee Break Trading Dynamics: The Mystery Behind the Trade Jason Kelley – Healthcare Trader, Needham & Co. Patrick Connors – Healthcare Trader, Greenwich Prime Moderator: Todd James – Director of Capital Markets Analysis, The Trout Group From IND to AdComms with Your Scientific Narrative Frank Carillo – President and Managing Director, ECG, Inc. Business Development for Biotech Casi DeYoung – VP, Business Development, Reata Pharmaceuticals Vipula Tailor – Director, Worldwide Business Development, GlaxoSmithKline Moderator: Alan Roemer, MBA, MPH – Managing Director, The Trout Group Closing Remarks Jonathan Fassberg – CEO, The Trout Group Cocktail Reception, Park Avenue Penthouse Lounge
Implications of Healthcare Reform on FDA Processes
Angeliki Kotsianti, Director, Global R&D Pfizer Dr.Kotsianti received her MD, PhD in Molecular Pathology at the Aristotelian University of Thessaloniki, Greece. In 1994, after academic tenures in Greece and Switzerland she joined the Pathology Department of Mount Sinai Medical Center, New York, as a faculty member and later the Molecular Pathology Department at Memorial Sloan‐Kettering, New York. In 2002, she moved to the Biotech world and became a strong pioneer developing first generation diagnostic and prognostic tests for different tumor types, based on Systems Pathology approach. Dr. Kotsianti has been granted numerous patents in the USA and EU for her work in Systems Pathology. Late 2006 she merged her scientific, clinical and industry experience and joined Pfizer Inc. in the Global Clinical Technology Group, under the Human Health Technologies Group in New York, supporting the oncology portfolio. Shortly after, she was entrusted Global Medical position in the Oncology Group leading Global Clinical Trials for Pfizer Inc. for novel targeted and immunotherapeutic compounds for cancer patients. In the last 3 years, she became Global Oncology Lead in the Center of Excellence in the Established Product Business Unit of Pfizer. Her responsibilities are to support, defend and manage multiple different complex medical and product issues around the globe, regarding safety, efficacy, risk: benefit indications, labeling, market authorizations and a plethora of initiatives involving over 100 Oncology products worldwide, including generic and bioequivalent submissions. Carlos Cordon‐Cardo, Chair of Department of Pathology Mount Sinai Medical Center Carlos Cordon‐Cardo, MD, PhD, Chair of the Dept. of Pathology at the Mount Sinai Medical Center is a renowned physician‐ scientist known widely for his research in experimental pathology and molecular oncology. A distinguished leader in the mechanism of tumor suppression, Dr. Cordon‐Cardo’s research has focused on analyses of multidrug resistance and alterations of tumor suppressor genes in human cancer. He pioneered the development and implementation of an oncologic molecular pathology discipline, and recently he participated in the creation of the "systems pathology" platform, and is widely known as an expert on the development of biomarkers for tumor pathogenesis and predicting clinical outcome.
Implications of Healthcare Reform on FDA Processes
Rhonda Greenapple, President and Founder Reimbursement Intelligence Rhonda spent her career focused on assisting pharmaceutical, medical device, and biotechnology clients to gain greater access and reimbursement for their products. Her client’s products ranged from unique chemical entities to highly competitive therapeutic categories. Reimbursement Intelligence’s expertise and focus is dedicated to driving access and reimbursement initiatives from Phase II through the product lifecycle and serve to maximize commercial success. Rhonda’s clients include biotech companies looking at clinical trial design, reimbursement planning, licensing opportunity and pipeline asset evaluations, as well as exit strategies. Over the past 15 years, she has been involved in the reimbursement launch planning for over 40 products. She has spoken both at professional meeting both domestic and internationally on a range of topics and has been a columnist in Fierce Pharma Industry Voices on reimbursement issues. Rhonda received her B.S. from Cornell University and received her Master of Science in Public Health from the University of North Carolina. Rosemary Mazanet, Senior Advisor The Trout Group, LLC Dr. Mazanet trained in medicine and Heme/Onc at the Brigham and Women’s Hospital and Dana Farber Cancer Institute in the 1980’s and started in the Biotech industry at Amgen, where she was head of Neupogen Clinical Development, and then Oncology Clinical Development. She has been a presenter in front of an FDA advisory panel on more than one occasion, and was well known to the investment community that followed Amgen. In 1998, she joined Oracle Partners, LP where she was a well respected buy‐side analyst. More recently, she has been a general partner of Apelles Investment Management, LP, has been Interim CEO for a number of transitioning companies, both public (Access Pharmaceuticals) and private (Diabetes America, Inc) as well as start up (Breakthrough Therapeutics, LLC). She has served on numerous boards, and is currently a co‐Chair for the University of Pennsylvania Making History Campaign ($3.5bn), where she has been a member of the Executive Committee for the Health System since 2002.
Implications of Healthcare Reform on FDA Processes
Angeliki Kotsianti, M.D., Ph.D. – Director, Global R&D, Pfizer
Rhonda Greenapple, MSPH – President and Founder, Reimbursement Intelligence
Moderator: Rosemary Mazanet, M.D., Ph.D. – Senior Advisor, The Trout Group
Implications of Healthcare Reform on FDA Processes
Social Media: New Trends in Online Marketing
Justin Schreiber, President and CEO Executive Video Justin Schreiber leads Executive Video’s strategy and business development efforts. He is a strong proponent of video communication strategy and assists the firm’s clients with the development and distribution of compelling video content that positively influences share price, liquidity, and revenue. He has produced videos with more than 300 companies in the healthcare and technology space. He was the former President of OneMedForum, a conference for early stage private and public life science companies. Prior to this Mr. Schreiber served as Director of Business Development for Tefen USA, a global life sciences consultancy. He began his career working as a financial specialist for Gain Capital, a leading provider of online foreign exchange trading, asset management, and B2B forex services. He holds a BS in International Business from Elizabethtown College and a BA in International Management from the ICN École de management in Nancy, France.
Social Media: New Trends in Online Marketing
Ms. Peters received her BA from McGill University in Montreal, Canada and her MA in Commercial Diplomacy from the Monterey Institute of International Studies in Monterey, California. Gary Disbrow Biomedical Advanced Research and Development Authority Dr. Gary Disbrow joined BARDA in January of 2007 and began working on the smallpox vaccine program. Dr. Disbrow played a key role in awarding a contract for the modified vaccinia Ankara (MVA) vaccine and was instrumental in obtaining Secretarial approval for Advance Payment and Milestone payments awarded in the contract based on Project BioShield (PBS) and the Pandemic and All Hazards Preparedness Act (PAHPA) legislation. Dr. Disbrow accepted the position of Deputy Director CBRN Division of Countermeasures in October of 2008 and has been overseeing the budget for both advanced research and development and PBS efforts. Prior to joining BARDA Dr. Disbrow was an Assistant Professor of Oncology and Pathology at Georgetown Medical Center where he worked on the development of the human papillomavirus vaccine (HPV) in addition to the virus like particle (VLP) technology. Gary attended the University of Rochester and Georgetown University for his undergraduate and Ph.D. respectively.
Exploring Innovative Financing
Danielle Peters, Consultant Fabiani & Company Since 2004, Ms. Peters has assisted Fabiani & Company clients in seeking federal funding and partnerships for research and commercialization of novel technologies. Ms. Peters has represented companies in the life sciences, defense technology and green technology sectors. Ms. Peters manages client relationships with federal agencies and Congress and has a proven track record in successfully positioning clients for federal funding and federal partnership opportunities. On policy matters, Ms. Peters is engaged in issues that include patent reform, Small Business Administration Authorization, public health preparedness and incentives for clean energy commercialization.
John Partigan, Partner Nixon Peabody John Partigan concentrates his practice in federal securities law matters and mergers and acquisitions. His securities practice includes representing issuers in connection with primary and secondary public offerings of debt and equity securities, including initial public offerings, stock repurchase programs and private placements of debt and equity securities. He is regularly involved in advising clients regarding disclosure requirements under the federal securities laws. Mr. Partigan is the chairman of the firm’s national Securities Practice Group. He is a member of the NASDAQ Listings Qualifications Panel (2004‐present). Mr. Partigan’s mergers and acquisitions practice includes public and privately negotiated acquisitions and divestitures in a variety of industries, including digital media, broadcast and cable television, publishing, telecommunications, energy and software. Karin Hehenberger, SVP, Strategic Alliances Juvenile Diabetes Foundation Dr. Hehenberger holds M.D. and Ph.D. degrees from the Karolinska Institute in Stockholm, Sweden, where her thesis focused on diabetic complications. She continued her research as a JDRF post‐doctoral fellow at the Joslin Diabetes Center at Harvard Medical School. She then moved into the business aspect of medicine, as a strategic management consultant at McKinsey & Co., where she focused on projects related to diabetes. Dr. Hehenberger also has experience in public and private equity, having been a partner in a European venture capital firm, a buyside healthcare equity analyst, and on the senior management team of a public biotech company. Dr. Hehenberger is on the board of the Rolf Luft Foundation for Diabetes Research and the Core Sight Council. In addition, she serves as a faculty member at the department of of Molecular Medicine of the Karolinska Institute, as Senior Advisor, Biotechnology and Medical Innovations. Michael Herman, SVP, Research & Investments Royalty Pharma Mr. Herman joined Royalty Pharma at inception. From 1994 to 1996, Mr. Herman consulted for several financial concerns, including Apollo Advisors, Société Génerale and International Technology Investment Managers, the general partner of the “proof of principle” funds. From 1991 to 1994, Mr. Herman was an analyst in the fixed income division of Lehman Brothers. Mr. Herman received a BA with honors in Psychology and Economics from the University of Michigan.
Exploring Innovative Financing
Christopher D. Earl Christopher D. Earl, PhD is an entrepreneur and investor with track record of fostering company growth based on innovative products and underserved markets, both as a venture capitalist and CEO. He has broad experience as a CEO and board member of science‐based, not‐for‐profit organizations, leading research, policy and advocacy efforts. Most recently, Dr. Earl was the first President and CEO of BIO Ventures for Global Health (BVGH), a not‐for‐profit organization harnessing biotechnology industry R&D to treat infectious diseases of the developing world. Previously, he served as Managing Director of Perseus Capital, LP, and the Perseus‐Soros BioPharmaceutical Fund, L.P. Earlier, Dr. Earl was President and CEO of Avitech Diagnostics, Inc., and a General Partner of Plant Resources Venture Funds. Dr. Earl serves on the Board of Directors of the Infectious Disease Research Institute, Asuragen, Inc., Mirna Therapeutics, Inc. and the Nature Conservancy of Maryland/DC, and advises Merck & Co.'s new Global Health Innovation internal venture investment group. He is a Trustee of the Committee for Economic Development. Dr. Earl received a BA in Biology from the University of Pennsylvania, and a PhD in Cellular and Developmental Biology from Harvard University.
Exploring Innovative Financing
Exploring Innovative Financing
Jan Schultink, CEO Idea Transplant Jan Schultink is an internationally recognized expert in presentation design. After a decade as a strategy consultant with McKinsey & Company, Jan is now the CEO of Idea Transplant, designing professional presentations for conferences, sales pitches, and investor relations. His blog, blog.ideatransplant.com is one of the world's most read resources on the subject of presentation design.
\
Investor Communication: Presentation Content & Style
Exploring Innovative Financing
Investor Communication: Presentation Content & Style
Frederick W. Driscoll, CFO Novavax, Inc. Frederick W. Driscoll joined Novavax in August 2009 as Chief Financial Officer after more than 30 years of financial management and operational experience in the biotechnology and medical device sectors. In 2007, he joined Genelabs, Inc., a publicly traded biotechnology company developing novel small molecules targeted at infectious diseases, where he served as Chief Financial Officer and became Chief Executive Officer prior to the company’s acquisition by GlaxoSmithKline. From 2000 to 2006, Mr. Driscoll was employed by OXiGENE, Inc., initially as Chief Financial Officer and subsequently as Chief Executive Officer. Mr. Driscoll has also served in senior financial positions at Collagenesis, Inc. and Instrumentation Laboratory. Richard Katz, CFO Icagen, Inc. Dr. Katz has been our senior vice president, finance and corporate development, and chief financial officer since April 2001. From August 1996 to 2001, Dr. Katz worked in the Investment Banking Division of Goldman Sachs, an investment banking firm, most recently as a vice president in the Healthcare Group. Prior to joining Goldman Sachs, Dr. Katz earned a Masters in Business Administration from Harvard Business School where he graduated as a Baker Scholar. Dr. Katz earned his M.D. from the Stanford University School of Medicine and completed an internship in general surgery at the Hospital of the University of Pennsylvania. Dr. Katz received his A.B. in applied mathematics with high distinction from Harvard University.
Minimizing Dilution in Capital Raising
Dennis Turpin, SVP and CFO AEterna Zentaris, Inc. Dennis Turpin joined the Company in August 1996 as Finance Director before being appointed Vice President and Chief Financial Officer in June 1999. Since being with Æterna Zentaris, M. Turpin has been actively involved in several financing activities such as public offerings and is very committed to investor relation activities on an international level. Prior to joining Æterna Zentaris, Mr. Turpin was with Coopers & Lybrand (now PricewaterhouseCoopers), Chartered Accountants, for over ten years.
Shalini Sharp, CFO Agenus, Inc. Shalini leads our finance and corporate development functions. Shalini joined Agenus in 2003 as Director of Strategic Planning. She was promoted to Senior Director, Strategic Planning and Corporate Development in 2005 and Vice President, Chief Financial Officer in 2006. Prior to joining Agenus, Shalini was Director of Strategic Planning at Elan Corporation, plc, where she served as chief of staff to the chairman of the board during the restructuring process and she drove to completion a number of strategic corporate and financial transactions. Shalini was previously a management consultant at McKinsey & Company, specializing in pharmaceuticals and medical devices. She holds a BA and MBA from Harvard University.
Dean Colucci, President and General Counsel McNicoll, Lewis & Vlak Mr. Colucci joined the firm from DLA Piper where he was a partner in the Corporate and Finance group for over 10 years. Prior to being a partner at DLA Piper, Mr. Colucci was at Cadwalader Wickersham & Taft. During his 17 year legal career, Mr. Colucci developed a broad based corporate and finance practice that extended across capital markets, cross‐border M&A, global infrastructure development and finance, and asset‐ based finance. In the capital markets area, Mr. Colucci has been at the forefront of developing several “At‐the‐Market Offering” products. He has been lead underwriter’s counsel in over 50 ATM transactions acting on behalf of 11 different investment banks. These deals raised more than $6 billion in equity capital for companies in the technology, life sciences, real estate investment trust, energy, transportation, and oil and gas sectors. Additionally, Mr. Colucci was intimately involved in structuring ATM products for both common and preferred stock as well as for dual listed issuers in Canada and Israel. Mr. Colucci has an AB from Cornell University, an MA from Columbia University, and a JD from the George Mason University School of Law. Mr. Colucci holds his Series 7, 63, and 24 licenses.
Minimizing Dilution in Capital Raising
Minimizing Dilution in Capital Raising
Christiana Bardon, Chief Investment Officer Burrage Capital Christiana Bardon is a Managing Director at Burrage Capital, a hedge fund focused in biotechnology and healthcare. Previously, she was a health care analyst at Fidelity Investments. Chris earned her MS/BS from MIT, her MD from Harvard Medical School and her MBA from Harvard Business School. While at Harvard Medical School, Christiana was the recipient of a Howard Hughes fellowship. She also completed a residency in internal medicine at the Brigham and Women’s Hospital. David Sable, Portfolio Manager Special Situations Fund David Sable MD, directs healthcare and life science investing for the Special Situations Funds and is portfolio manager of the Special Situations Life Sciences Fund. After graduating from the Wharton School and the University of Pennsylvania School of Medicine, residency in obstetrics and gynecology at New York Hospital ‐ Cornell Medical Center, fellowship at Brigham and Women's Hospital, and clinical practice at Harvard Medical School and MIT, he co‐founded the Institute for Reproductive Medicine and Science at Saint Barnabas Medical Center in New Jersey. After leaving clinical medicine at age 43, Dr. Sable managed a proprietary healthcare portfolio at Deutsche Bank before joining the Special Situations group. Dr. Sable is an adjunct in the department of biology at Columbia University, and teaches “Entrepreneurship in Biotechnology” at Columbia’s Graduate School of Arts and Sciences, has delivered keynote addresses to the American Fertility Society; and appeared on the CBS Morning News and ABC World News Tonight. Fara Berkowitz, Managing Director Meadowvale Partners, LLC Fara is a Managing Director & Head of Research at Meadowvale Partners. She has 10 years of healthcare and 6 years finance experience. Previously, Fara was a biotechnology & specialty pharmaceutical analyst at Sivik Healthcare and worked at Goldman Sachs in the Equity Re‐ search Group, covering the specialty & generic pharmaceuticals sector where she launched the first ever generic sector coverage. Fara earned her MBA and Certificate in Healthcare Management from Duke University and Doctor of Pharmacy & B.S. from Rutgers College of Pharmacy.
Communication, Targeting & Analysis Communication, Targeting & Analysis
Buy‐Side Perspectives: Buy‐Side Perspectives:
Thomas Fechtner, Vice President The Trout Group Mr. Fechtner joined the firm in 2001 and has been involved in a wide variety of activities at Trout. His language skills, knowledge of the European markets, and relationships have helped Trout clients expand their reach into Europe. Recently, Thomas was the keynote speaker at a CEO‐CFO event in Germany about the US market, with an audience of more than 100 CEOs. His experience prior to joining the firm includes the sales of financial products and business communications. His role in investor relations for both domestic and international clients includes many aspects, such as investor targeting and road show outreach/logistics, implementing strategic planning, developing conference call scripts and investor audits. He also plans and advises biotechnology related investor conferences and assists in developing effective websites for clients. Thomas completed his studies at the University of Augsburg in Germany. He has earned the honorary Trout title of Global Concierge. He also holds a Series 7 securities license.
Communication, Targeting & Analysis
Buy‐Side Perspectives:
Tom Brakel, Senior Portfolio Manager Federated Investors, Inc. Dr. Thomas M. Brakel is a senior portfolio manager and senior investment analyst at Federated Investors, Inc. Prior to joining the firm in 2003, he was a vice president and senior analyst covering the biotechnology sector at New Vernon Associates, Inc. Previously, Dr. Brakel served as a portfolio manager at Biopharma Management Company from 2000 to March 2002. Prior to that, he was employed at BankInvest A/S. Before that, Dr. Brakel was a security analyst at Mehta Partners L.L.C. Earlier, he was the manager of new business development at Organon, Inc., a pharmaceutical subsidiary of Akzo Nobel. Previously, Dr. Brakel served as an analyst for the BioPharma Fund. He began his investment career in 1998. Dr. Brakel obtained an M.D. from the Rotterdam Medical School at Erasmus University of Rotterdam and M.B.A. from the Graduate School of Business at Stanford University. He is fluent in Dutch and German.
Buy‐Side Perspectives: Communication, Targeting & Analysis
Jason holds a PhD in neuroscience and a Bachelor’s degree in biology from Imperial College London. Joshua Schimmer, Managing Director Leerink Swann Joshua Schimmer, M.D., is a Managing Director, Biotechnology analyst covering mid and large‐cap biotechnology companies for Leerink Swann. Prior to joining the firm, Dr. Schimmer was a Managing Director for FTN Equity Capital Markets Corp, where he covered mid and large‐cap biotech companies. Before that, he spent two years as Healthcare Equities Analyst for buyside firm, Davidson Kempner Capital Management, LLC. Dr. Schimmer previously was a Director in Biotechnology research at Cowen & Company for three years, and began his career in biotechnology equity research at Deutsche Bank Securities. He holds a Doctor of Medicine Degree from the University of Toronto and a Master in Business Administration degree from Harvard University. Dr. Schimmer completed his Internal Medicine residency at the University of Toronto, as well as a fellowship in Rheumatology, where he was Chief Fellow.
Sapna Srivastava, Research Analyst Goldman Sachs Sapna Srivastava is the senior large cap biotechnology analyst at Goldman Sachs since June 2010. Prior to that, she was an executive director and senior security analyst covering emerging to mid biotechnology at Morgan Stanley for over five years. She started her career as a security analyst at J.P.Morgan Securities in 1999. Ms. Srivastava obtained a Ph.D. in Neuroscience in 1999 from New York University Medical Center and a B.S. from the University of Bombay, India in 1994.
Sell‐Side Perspectives: Analyzing Opportunities in a Dynamic Sector & Marketplace
Jason Butler, Research Analyst JMP Securities Jason Butler is a Vice President and research analyst covering the biotechnology industry. Prior to joining JMP, Jason served as a senior associate equity analyst at Rodman & Renshaw covering biotechnology companies focused on therapies for metabolic and infectious diseases.
Franklin Berger, Managing Director FMB Research
As a senior portfolio manager on the buy‐side, Mr. Berger worked at Sectoral Asset Management as a founder of the small‐cap focused NEMO Fund from 2007 through June 2008. Mr. Berger has spent 12 years in sell‐side equity research, most recently as Managing Director, U.S. Equity Research, J. P. Morgan Securities, Inc., from May 1998 to March 2003. During his five years at J. P. Morgan Securities, Inc., he was involved with the issuance of over $12 billion in biotechnology company equity or equity‐linked securities. He was associated with several notable financings in the biotechnology sector including the Genentech IPO, the largest biotechnology financing ever executed, the first large Celgene Corporation financings as well as several large‐cap biotechnology companies in their rapid growth phase. Mr. Berger began his career as a sell‐side analyst at Josephthal & Co. in 1991, subsequently moving to Salomon Smith Barney in 1997 serving as Director, Equity Research and Senior Biotechnology Analyst. The Wall Street Journal selected Mr. Berger as the No. 1 ranked biotechnology analyst in its All‐Star Analyst Survey in 1997 and No. 2 ranked in the WSJ’s 2000 Survey. In 2002, Institutional Investor Magazine ranked him on J. P. Morgan’s 3 rd‐placed All‐Star Research Team. In 2000, he became a Founding Fellow of the Biotechnology Study Center at New York University School of Medicine. Mr. Berger received his MBA degree from Harvard University in 1975; Johns Hopkins University conferred both his MA and BA degrees in 1971 and 1972, respectively.
Sell‐Side Perspectives: Analyzing Opportunities in a Dynamic Sector & Marketplace
Mr. Berger started his consulting practice in 2003 after leaving J. P. Morgan Securities, Inc. as their head of biotechnology research. His clients are exclusively biotechnology industry participants including major biopharmaceutical firms, mid‐capitalization biotechnology companies, specialist asset managers and venture capital companies. Assignments include business development, strategic advisory/financings, partnering and clinical trial strategy.
Sell‐Side Perspectives: Analyzing Opportunities in a Dynamic Sector & Marketplace
Gur Roshwalb, Vice President Venrock Gur joined Venrock in 2008. Prior to joining Venrock, he was a vice president and senior research analyst at Piper Jaffray & Co., focusing on specialty pharmaceuticals and small cap biotech companies. In this role, Gur was responsible for analyzing; valuing and publishing research on both publicly traded and privately held biotech and specialty pharmaceutical companies. Gur was trained in internal medicine at the Mount Sinai Medical Center, New York, where he also served as chief resident, and subsequently spent several years in private practice as an internist in New York. Jay Cecil, Managing Director Caxton Advantage Jay Cecil joined Caxton Advantage in 2006. Jay has 14 years of experience in the life sciences industry. Prior to joining the Fund, he was a Vice President in the Life Sciences Investment Banking Group at Piper Jaffray. Before Piper Jaffray, Jay worked within the Health Care Investment Banking Group at Montgomery Securities. During his years in life sciences banking, Jay completed over 60 financing and acquisition transactions worth over $5.6 billion for a range of life science clients including Anesta, MGI Pharma, Biomarin Pharmaceuticals, Alexion Pharmaceuticals and ILEX Oncology. Since joining the fund, Jay has played an active role in a number of new investments, including VIVUS, Corthera, Regado Biosciences and Anthera Pharmaceuticals. Jay earned an MBA from The Wharton School, University of Pennsylvania and an MS in Biotechnology from the University of Pennsylvania with a concentration in Immunology. He graduated Phi Beta Kappa from Lehigh University with a degree in Economics.
Funding Innovation: Accessing Risk Capital
Funding Innovation: Accessing Risk Capital
Mike Nowak, Managing Director Yorkville Advisors Mike leads Yorkville's Healthcare Investment Team with over twenty years' experience structuring innovative financing products for private equity and mid‐stage firms. Prior to joining Yorkville Advisors, Michael was a General Partner at TVM Capital, a billion dollar Euro‐US venture fund. He also has entrepreneurial, business development and investment experience from work as a cofounder of the Xerox Venture Lab at Xerox PARC, as a VP Business Development for an emerging high tech consulting practice at McKinsey & Co., and as a Manager of two $100M investment programs at the Advanced Technology Program at NIST, US Department of Commerce. Michael earned an MBA from the Wharton School at the University of Pennsylvania and a PhD in Physics from the University of California, Santa Barbara. He worked as a post‐doctoral scientist at Bell Labs (Bellcore), Princeton University, and at the CEA research labs in Saclay, France. He received his BA in Physics from Cornell University in Ithaca, NY.
Funding Innovation: Accessing Risk Capital
Jason Kelley, Managing Director, Institutional Sales &Trading, Healthcare Trader Needham and Company Jason has over 15 years of sales and trading experience. He covers large hedge funds and institutions for Needham and has been a top producer over his tenure. Needham is a leader in small cap growth research, investment banking and trading. Patrick Connors, Founder, Managing Partner Greenwich Prime Trading Group Mr. Connors has been a trader for almost two decades, with a special expertise in the health care, biomedical, and pharmaceutical industries. He began his career at Herzog, Heine & Geduld in 1992 serving as a trading assistant. In 1994, he left to become an equity trader at Furman Selz Prime Trading Group. Subsequently, the firm was acquired by ING Barings, which in turn was acquired by ABN Amro in April of 2001. The team separated from ABN AMRO and began life as the independent Greenwich Prime a few months later. Mr. Connors earned his B.A. degree in Economics from Lehigh University. Greenwich Prime Trading Group, LLC is the pioneer of outsourced trading services for institutional clients. Greenwich's clients include large institutions, midsize funds, mutual funds, startups, funds of funds, private equity funds, family offices, endowments, and companies conducting corporate share buybacks. Greenwich offers access to a wide universe of brokers, research, and trading information. The firm serves exclusively as an agent of the client, and its business consists only of our core competency of trading. Todd James, Director of Capital Markets Analysis The Trout Group Mr. James manages Trout’s Capital Markets Analysis Desk. The CMA Desk provides both corporate clients and Wall Street with sector related market analysis and services. Todd has experience assisting Companies in their understanding of Wall Street, investor targeting, scenario analysis, and financings. He has done extensive research in trading strategies, technical analysis and activist investing within the biotech sector. He manages Trout’s relationship with its trading partner, Greenwich Prime Trading Group, to help provide liquidity to Trout’s clients and fund managers. He joined the firm in 2006 from the Thomson Financial Capital Markets Intelligence Biotechnology Team.
Trading Dynamics: The Mystery Behind the Trade
Trading Dynamics: The Mystery Behind the Trade
Trading Dynamics: The Mystery Behind the Trade
From IND to AdComms with Your Scientific Narrative
Frank Carillo, President and Managing Director ECG, Inc. Frank Carillo is President and Managing Director of ECG, the communication strategy company. Under Frank’s guidance, ECG’s healthcare practice consultants have achieved an impressive level of success. Since 1995, they have maintained a success rate of nearly 85% on positive votes in FDA Advisory Committees for product approvals. Frank himself has supported hearings and negotiations in over 20 different therapeutic areas. In addition, he and his team have supported hearings and negotiations for nearly 100 different teams preparing for Advisory Committee Meetings. Beyond Advisory Committee Meeting product approvals, Frank’s communication strategy and coaching have helped teams prepare special issue hearings, negotiating study designs and risk management plans, and marshalling support for ground‐breaking therapies and issues. Frank and ECG have a strong record of success in building the explanations and advocacy necessary for helping regulators and academicians see the benefits in new data while maintaining appropriate context around risk. In the dynamic and highly charged world of healthcare delivery and management, Frank and his partners also consult and coach CEOs and senior executives of pharmaceutical companies, health care providers, experts from academia, legislators and consulting firms on strategies that address this volatile national concern. Frank and his partners are rhetoricians and therefore valued by the popular media as communications experts. Their opinions and analysis create a demand for appearances on radio, TV and in print. Their comments and by‐lines about argumentation and high‐ stakes communication continue to appear in hundreds of newspapers, professional and trade journals and popular magazines. They appear globally on CNN, ABC, NBC, CNBC, CBS, and Fox and are regular contributors to the New York Metro media. Frank is also sought after as a speaker for professional and medical societies and has presented at scores of meetings globally. He recently presented on regulatory communication at UC San Francisco’s American Course on Drug Development and Regulatory Sciences. He most recently was a guest speaker at invivodata PROficiency 2011 where he discussed the emerging role of PRO in both pre‐ and post‐approval; he did this in the context of ECG’s recent success preparing a client for a MEDCAC meeting. Frank is a graduate of the Wharton School of Business at the University of Pennsylvania. He is also a member of The Princeton Club of New York and the Union League of Philadelphia and was visiting communications faculty at Loyola University New Orleans from 1987 to 2005.
From IND to AdComms with Your Scientific Narrative
Casi DeYoung, VP, Business Development Reata Pharmaceuticals Ms. DeYoung is currently Vice President, Business Development at Reata Pharmaceuticals in Dallas, Texas. Previous roles have also included alliance management, portfolio management, commercial operations and management consulting in biotech pharmaceutical companies in the US and abroad. Prior to Reata, she served as Vice President, Business Development for ODC Therapy. She also held U.S. and global positions at EMD Pharmaceuticals, the U.S. subsidiary of Germany‐based Merck KGaA, now Merck‐Serono. Ms. DeYoung began her career in the pharmaceuticals business with Accenture. She received a B.S. degree in Chemistry and Mathematics from Southwestern University and an M.B.A. from the University of Texas. Vipula Tailor, Director, Alliance Management, Worldwide Business GlaxoSmithKline Vipula has over 15 years of international business development, licensing, R&D, manufacturing, operations, management and commercialization experience within pharmaceuticals, medical devices/diagnostics, consumer products and Healthcare arenas. As a former Senior Healthcare Management Consultant, Vipula was responsible for strategic and structured deals for four of the top 10 pharmaceutical/healthcare companies. She was directly responsible for Business Development and Alliance management, M&A/strategic partnerships at country (Kimberly‐Clark and Wyeth), regional (J&J Europe) and global levels (GSK). Vipula holds an MBA from University of Phoenix, MS in Medical Immunology from the London University and Bachelors in Microbiology. She is also a board member of Healing Hands of Joy (HHOJ), a non‐profit foundation helping women with fistula to reintegrate back in the society and become health ambassadors in Ethiopia.
Business Development for Biotech
Business Development for Biotech
Alan S. Roemer, Managing Director The Trout Group Mr. Roemer has over 18 years of experience in the life sciences industry. He joined the Trout Group in 2009 from Zelos Therapeutics, where he served as Chief Financial Officer & Treasurer and was responsible for all finance, accounting, administration, legal, human resources, information technology and investor/media relations functions. r was at Pharmasset (Nasdaq: VRUS) from 1999‐2008. Prior to joining Zelos, Mr. Roeme He was Pharmasset’s first full‐time management hire, then responsible for developing the early stage operational infrastructure, fundraising transactions, business development and investor relations. He raised over $100 million of private and public (IPO) equity for Pharmasset. Prior to Pharmasset, Mr. Roemer was a healthcare consultant for Booz‐Allen & Hamilton and Deloitte Consulting, and he held various operational roles at Bank of America. Mr. Roemer received a Bachelor of Science in Business Administration from Georgetown University and M.B.A. and M.P.H. degrees from Emory University's Goizueta Business School and Rollins School of Public Health. He also holds Series 7, 79 and 63 securities licenses.
Business Development for Biotech
Jonathan Fassberg, CEO The Trout Group Mr. Fassberg is the Founder and Chief Executive Officer of The Trout Group. He has worked in the life sciences industry for nearly 20 years and been an advisor to senior management of over 100 companies, both public and private. Prior to founding Trout in 1996, Jonathan was a sell‐side analyst at a healthcare‐focused investment bank. Before his career on Wall Street, Jonathan spent four years at DuPont Pharma in various sales and marketing positions. Jonathan holds a Bachelor of Science degree in biology and chemistry from The University of North Carolina – Chapel Hill and a Master of Business Administration degree in finance from New York University’s Stern School of Business. He also holds Series 7, 24, 79 and 63 securities licenses.
Closing Remarks
The Trout Group cordially invites you to our
7th Annual Wall Street Unplugged Cocktail Reception
Location: Gansevoort Park Avenue Hotel's Penthouse Lounge Time: 6:00 – 8:00 pm
Overlooking Manhattan's skyline, we welcome you to join us for cocktails and hors d'oeuvres while networking with life science executives, fellow Wall Street colleagues and other industry professionals. Celebrating 15 years in business, the Trout Group is especially looking forward to this event, which last year attracted over 75 companies from the life science and investment community.
Global Team
Global Client Roster
We provide a full range of investor relations & strategic advisory services to life science, clean technology & sustainability companies.
NOTES
NOTES
NOTES
NOTES
NOTES
